Herbicide-resistant weeds challenge producers and agrochemical companies with a vexing issue that some refer to as a ‘wicked ...

The ALS research landscape is evolving rapidly, with groundbreaking advancements shaping the future of therapeutic ...

Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a study published in Neuron, ...

And what makes a new candidate drug called COYA 302, an investigational therapy for ALS, different? COYA 302 is a dual-mechanism investigational biologic combination therapy. To explore this ...

Researchers have developed a laboratory model that mimics the pathological aggregation of TDP-43, a key protein in ALS and ...

UCLA Health researchers say study findings uncover Huntington's disease mechanisms and pave new ways to develop treatments.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of new preclinical research in Free Radical Biology and Medicine, highlighting the role of edaravone in mitigating TDP-43 ...

Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a newly published study, ...